ArticleDiscover oncology2025
UNC93B1: a novel immune-related prognostic biomarker in breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- UNC93B1 drives IL-6/STAT3-dependent tumor-macrophage crosstalk and epithelial-mesenchymal transition in breast cancer.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Breast cancer (BRCA) is a prevalent and deadly disease among women. This study investigated the role of UNC93B1, a gene associated with immune function, in BRCA prognosis and immune infiltration. Differentially expressed mRNA (DEmRNA) data related to the prognosis and immunity of BRCA patients were obtained from TCGA, GTE, GEO, and ImmPort databases. The Kruskal-Wallis test was used to identify clinicopathological parameters associated with UNC93B1 expression. Univariate and multivariate COX regression analyses were performed to assess the impact of UNC93B1 expression and clinicopathological parameters on patient survival. We analyzed the target genes' relevant functions and signaling pathways through enrichment analysis. Furthermore, the relationship between UNC93B1 expression and tumor immune infiltration was examined using ssGSEA and Spearman correlation analysis. The findings demonstrated that high expression of UNC93B1 was associated with poorer prognosis in BRCA patients. UNC93B1 was also linked to race, N stage, pathological stage, and overall survival in BRCA patients and emerged as an independent prognostic factor. Functional enrichment analysis indicated significant enrichment of UNC93B1 in oncogenic and immune-related pathways. Moreover, UNC93B1 expression displayed significant associations with tumor immune cells and immune checkpoints according to ssGSEA and Spearman correlation analysis. Knockdown of UNC93B1 expression in BRCA cell lines (MDA-MB-231, SK-BR-3) suppresses their proliferation, invasion, and other phenotypes. These results suggest that UNC93B1 may be an immunologically relevant diagnostic and prognostic biomarker for BRCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.